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ABSTRACT
Acute leukemia is a constellation of rapidly progressing 
diseases that affect a wide range of patients regardless 
of age or gender. Traditional treatment options for 
patients with acute leukemia include chemotherapy 
and hematopoietic cell transplantation. The advent of 
cancer immunotherapy has had a significant impact on 
acute leukemia treatment. Novel immunotherapeutic 
agents including antibody- drug conjugates, bispecific 
T cell engagers, and chimeric antigen receptor T cell 
therapies have efficacy and have recently been approved 
by the US Food and Drug Administration (FDA) for the 
treatment of patients with acute leukemia. The Society 
for Immunotherapy of Cancer (SITC) convened a panel of 
experts to develop a clinical practice guideline composed 
of consensus recommendations on immunotherapy for 
the treatment of acute lymphoblastic leukemia and acute 
myeloid leukemia.
INTRODUCTION
The acute leukemias, including acute lympho-
blastic leukemia (ALL) and acute myeloid 
leukemia (AML), are rapidly progressing 
forms of leukemias defined by high percent-
ages of blasts in the blood and bone marrow 
and by the predominant lineages of malig-
nant cells.1 In 2020, an estimated 26,090 
cases of acute leukemias will be diagnosed in 
the US and 12,700 deaths are anticipated.2 
In children, leukemia is the most common 
hematologic malignancy, and the incidence 
of childhood leukemia has steadily increased 
every year.3 Advances in molecular diag-
nostics over the past several decades have 
further defined multiple disease subtypes, 
differentiated by the presence of specific 
genetic markers, which have informed risk- 
based treatment paradigms to reduce toxicity 
in low- risk patients while pursuing more 
aggressive therapies for those with a high risk 
of relapse.4–7
Standard treatment paradigms for acute 
leukemia have centered on high- intensity 
induction chemotherapy to achieve complete 
remission (CR) followed by allogeneic hema-
topoietic cell transplant (allo- HCT) in certain 
patients8–10 to eradicate residual disease 
through the “graft versus leukemia” effect 
mediated by the donor’s immune cells.11–13 
However, allo- HCT is not indicated for all 
patients and a major ongoing challenge in the 
field is that few chemotherapy- based options 
are effective following relapse after allo- HCT 
or for patients who develop chemotherapy- 
refractory disease.13 14
Immunotherapeutic approaches have 
dramatically altered the treatment land-
scape across a variety of disease settings, 
including hematological cancers. In recent 
years, novel agents including monoclonal 
antibodies, bispecific antibodies, antibody- 
drug conjugates (ADCs), and engineered 
chimeric antigen receptor (CAR) T cells have 
been approved by the US Food and Drug 
Administration (FDA), offering additional 
options beyond standard regimens and deep 
and durable responses in some patients.15–18 
Although ADCs may not be classified as a 
traditional form of immunotherapy, there is 
evidence of immunomodulatory activity by 
these agents.19
While immunotherapies for acute leukemia 
have demonstrated efficacy in a number of 
large- scale, randomized trials,15 20 21 clinical 
experience with some of these novel agents 
is still somewhat limited. To support the 
oncology community and provide expert, 
evidence- based recommendations, the 
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Society for Immunotherapy of Cancer (SITC) published 
consensus recommendations in December 2016 on 
the role of immunotherapy in the treatment of hema-
tological malignancies.22 Since 2016, however, rapid 
advances in the field have brought about a wider array of 
immunotherapy- based treatment options for each of the 
individual disease states discussed in the original guide-
lines: acute leukemia, lymphoma, and multiple myeloma. 
Thus, the SITC Cancer Immunotherapy Guidelines—
Hematologic Malignancies Subcommittee determined 
that stand- alone guidelines are needed. To form up- to- 
date recommendations on the use of immunotherapy 
for the treatment of patients with acute leukemia, SITC 
convened a panel of experts to develop a new clinical 
practice guideline. This publication represents an update 
to the previously published consensus statement based on 
a more recent assessment of the peer- reviewed literature 
and the clinical experience of expert panel participants. 
These recommendations are not intended to supplant 
sound clinical judgment but rather to provide clinicians 
with the most current thinking on how experts integrate 
immunotherapy into the treatment of patients with acute 
leukemia.
METHODS
SITC Acute Leukemia Immunotherapy Guideline Expert Panel
The SITC Acute Leukemia Guideline Expert Panel 
consisted of 17 participants, including medical oncol-
ogists, hematologists, a hematopathologist, a leukemia 
research nurse, and a patient advocate. Every clinical 
Expert Panel member reported previous experience/
knowledge regarding the use of immunotherapy for the 
treatment of patients with leukemia. The panel members 
met in person and communicated regularly via email and 
teleconference. In addition, they completed a survey (see 
online supplementary file 1) addressing clinical topics 
concerning the use of cancer immunotherapy for the 
treatment of patients with acute leukemia, which helped 
form the basis for these recommendations.
Consensus statement policy
The Institute of Medicine’s (IOM) Standards for Devel-
oping Trustworthy Clinical Practice Guidelines were used 
as a model to develop the consensus recommendations 
in this manuscript. IOM standards dictate that guideline 
development be led by a multidisciplinary team using 
a transparent process where both funding sources and 
conflicts of interest are readily reported. Recommenda-
tions are based on literature evidence, where possible, 
and clinical experience, where appropriate.23 For trans-
parency, a draft of this consensus statement was made 
publicly available for comment after journal submission. 
All comments were considered for inclusion into the 
final manuscript. This consensus statement is intended to 
provide guidance and is not a substitute for the profes-
sional judgment of individual treating physicians.
Evidence and consensus ratings
Recommendations were derived from evidence within 
the published literature along with responses to a clinical 
questionnaire that addressed current practices in the use 
or recommendation for use of immunotherapy agents 
(online supplementary file 1). SITC Cancer Immuno-
therapy Guidelines provide recommendations based on 
peer- reviewed literature and consensus within the expert 
panel. Consensus was defined as ≥75% agreement among 
expert panel members.
Conflicts of interest policy
As per SITC policy, expert panel members managed 
potential competing interests through disclosure of all 
financial relationships that might result in actual, poten-
tial, or perceived conflicts of interest. No commercial 
funding was provided to support the expert panel, litera-
ture review, or the preparation of this manuscript.
Literature review process
The MEDLINE database was used to search the scientific 
literature for current therapies related to acute leukemia 
and immunotherapy, including clinical trials, meta- 
analyses, practice guidelines, and research in humans.
The search terms included among others “acute 
lymphoblastic leukemia,” “acute myeloid leukemia,” 
“blinatumomab,” “inotuzumab ozogamicin,” “tisagen-
lecleucel,” “CAR T AND leukemia,” “gemtuzumab 
ozogamicin,” “immunotherapy AND leukemia,” and 
“immunotherapy toxicity.” Manuscripts retrieved by the 
search were screened to include only papers with clini-
cally accurate and relevant information and to remove 
duplicate articles from independent searches. The refer-
ence library was supplemented with additional articles 
identified by the panel as appropriate and necessary for a 
comprehensive literature review, resulting in a final bibli-
ography of 141 manuscripts.
DIAGNOSTICS PRIOR TO IMMUNOTHERAPY FOR NEWLY 
DIAGNOSED PATIENTS WITH ACUTE LEUKEMIA
A number of clinical guidelines have been developed 
for the workup and diagnosis of acute leukemia. Initial 
workup provides disease classification, risk stratification, 
and a better understanding of both disease biology and 
potential treatment options.1 5 6 24–26 Selection of appro-
priate diagnostics to initiate immunotherapies is under 
investigation. Only in a select few situations has consensus 
been achieved on how to determine whether a patient 
is a strong candidate for immunotherapy. Further, if a 
patient is eligible for two different immunotherapies, it 
is challenging to identify the treatment option that will 
provide maximal benefit. Potential diagnostic evaluations 
for patients with acute leukemia being considered for 
immunotherapy are discussed below.
A number of diagnostics are available for the initial 
workup of a patient suspected to have acute leukemia. 
Workup typically includes history and physical 
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examination, complete blood counts (CBC) and leuco-
cyte differential counts, platelets, electrolytes, liver func-
tion tests, prothrombin time (PT), partial thromboplastin 
time (PTT), international normalized ratio (INR), fibrin-
ogen, lactate dehydrogenase (LDH), uric acid, human 
leucocyte antigen (HLA) typing for patients who are 
candidates for allo- HCT, chest X- ray and CT/MRI scans if 
clinically indicated, echocardiogram, and a lumbar punc-
ture if neurological symptoms are present.5 6 24 27 Bone 
marrow biopsy/aspirate with cytogenetics (karyotype and 
fluorescence in situ hybridization (FISH)), immunophe-
notyping, and molecular studies including next genera-
tion sequencing, are performed to diagnose and classify 
disease characteristics. Cytochemical studies can also 
help to differentiate between ALL and AML, but do not 
traditionally replace immunophenotyping. Appropriate 
sensitivity of all assessment techniques must be verified 
to ensure that measurable/minimal residual disease 
(MRD) status can also be assessed in future management 
stages.24–26
Acute leukemia can be associated with a variety of 
genetic mutations that may serve as markers for MRD 
or be targetable with drugs. ALL can be associated with 
a variety of genetic mutations. The American Society of 
Clinical Oncology/College of American Pathologists/
American Society of Hematology (ASCO/CAP/ASH) 
guidelines for the workup of acute leukemia recommend 
a number of genetic tests to identify different mutations. 
A summary of the recommended molecular tests for ALL 
and AML is provided in table 1.
While molecular characterization may identify action-
able mutations for targeted therapies such as tyrosine 
kinase inhibitors, cell surface markers may be used to 
identify potential targets for immunotherapies. The 
National Comprehensive Cancer Network (NCCN) and 
the European Society for Medical Oncology (ESMO) 
guidelines, in addition to molecular testing, also 
recommend assaying for specific cell markers, such as 
CD19, CD20, and CD22 for ALL and CD33 for AML 
to assess eligibility for potential antibody- based thera-
pies.5 26 Importantly, however, current clinical pathology 
laboratories for CD19 and CD22 expression report only 
the presence or percent expression, which is often not 
an accurate representation of the number of molecules 
or the presence of subpopulations of leukemia cells that 
lack these markers.28 Subpopulations of CD19- negative 
or CD22- negative or low- expression leukemia cells may 
play an important role in eventual relapse. A retrospec-
tive analysis of flow cytometry archives found profound 
heterogeneity in CD22 and CD19 expression across 628 
B‐ALL cases. 29 Although such analyses remain strictly 
for research use at this point, with the increasing use of 
CD19- specific or CD22- specific immunotherapies, the 
heterogeneity in cell surface marker expression is likely 
to become an important consideration in the future.
Certain FDA- approved immunotherapies for the treat-
ment of patients with acute leukemia require specific 
disease characteristics for eligibility. For example, 
gemtuzumab ozogamicin (GO) for the treatment of 
patients with newly diagnosed or relapsed/refractory 
(RR) AML requires confirmation of CD33 positivity on 
malignant cells.30 The bispecific antibody blinatumomab 
that directs CD3 positive T cells to CD19- positive leukemia 
cells is approved for patients with B- cell ALCL (B- ALL) 
in first or second complete response (CR) with MRD 
positivity after induction therapy.16 20 31–35 Therefore, it is 
critical to perform phenotypic and molecular character-
ization of leukemic cells at diagnosis and to assist future 
MRD status assessment.6 24 25 36
Several ongoing clinical trials are evaluating the safety 
and efficacy of emerging immunotherapies directed 
against specific cell surface markers. For example, 
MGD006, a dual- affinity T cell retargeting molecule 
designed to target CD123- positive cells for recognition 
and elimination by CD3- expressing T lymphocytes, is 
currently being evaluated in a phase I dose- escalation and 
cohort expansion study in RR AML (NCT02152956).37 
Additionally, the CD33- directed ADC IMGN779 is under-
going evaluation in a phase I trial (NCT02674763).38 
Table 1 ASCO/CAP/ASH recommended genetic tests for 
ALL and AML6




KMT2A (MLL); IKZF1 (for B- ALL)
CRLF2 overexpression (for B- ALL)
NOTCH1 and/or FBXW7 (for T- ALL)







KIT (for CBF AML); TP53
RUNX1- RUNXT1/CBFB- MYH1 (for CBF 
AML)
*Characterization of pediatric ALL should also include ETV6- 
RUNX1, iAMP21, and trisomy 4 and 10.
†Results of RUNX1, ASXL1, and TP53 testing are recommended 
by NCCN guidelines for use in risk stratification and consideration 
for allo- HCT.5
‡Similar recommendations are made by the European Leukemia 
Net (ELN) group for AML with additional testing for mutations in 
the epigenetic regulator gene ASXL1 and FLT3- ITD allelic ratios, as 
well as cell markers.4
ALL, acute lymphoblastic leukemia; allo- HCT, allogeneic 
hematopoietic cell transplant ; AML, acute myeloid leukemia; 
ASCO, American Society of Clinical Oncology; ASH, American 
Society of Hematology; B- ALL, B- cell acute lymphoblastic 
leukemia; CAP, College of American Pathologists; CBF, core- 
binding factor; NCCN, National Comprehensive Cancer Network; 
T- ALL, T cell acute lymphoblastic leukemia.
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Guidelines for these and other emerging therapies will 
be discussed in the emerging immunotherapies section of 
this manuscript. Although many targeted therapies have 
not yet been FDA approved, experimental diagnostics 
may assist in referring patients to an appropriate clinical 
trial. A summary of recommended immunotherapy- 
centric diagnostic markers for approved therapies is in 
table 2.
Panel recommendations
 ► Cell markers at diagnosis and at the time of disease 
relapse should be performed to identify potential 
markers that drugs can be used for treatment.
 ► Upfront diagnostics for ALL should include the cell 
markers CD19, CD20, and CD22.
 ► Upfront diagnostics for AML should include the cell 
markers CD33 and CD123.
 ► CD19+ ALL patients may be eligible for blinatum-
omab or tisagenlecleucel (patients aged ≤25 years).
 ► CD22+ ALL patients may be eligible for inotuzumab 
ozogamicin.
 ► CD33+ AML patients may be eligible for GO.
IMMUNOTHERAPY FOR THE TREATMENT OF PATIENTS WITH 
ALL
Treatment of acute leukemia has rapidly evolved since 
the publication of “The Society for Immunotherapy of 
Cancer consensus statement on immunotherapy for the 
treatment of hematologic malignancies” in 2016.22 In the 
intervening years, novel immunotherapeutic approaches, 
such as ADCs, dual- affinity molecules such as bispecific T 
cell engagers (BiTEs), and highly successful CAR T cell 
therapies, have been approved by FDA and entered the 
clinic (table 3). Yet, these immunotherapies have specific 
indications that must be integrated with existing treat-
ment modalities.
Available agents and indications
The addition of immunotherapies to existing intensive 
chemotherapy regimens, targeted agents, and allo- HCT 
has fundamentally altered the treatment landscape for 
ALL, especially in the relapsed and refractory setting.
Published guidelines from ESMO26 and NCCN39 
provide recommendations for remission induction and 
consolidation therapies, maintenance therapy, central 
nervous system prophylaxis, and age- adopted protocols 
for standard treatment regimens.
Currently, three immunotherapies are FDA approved 
for the treatment of ALL: blinatumomab, inotuzumab 
ozogamicin, and tisagenlecleucel. Of note, approval for 
CAR T cell therapies often hinges on data from phase 
II trials, as was the case for the regulatory decision 
endorsing the use of tisagenlecleucel for adult patients 
Table 2 Recommended immunotherapy- centric diagnostic 














Table 3 FDA- approved cancer immunotherapy agents for ALL
Acute lymphoblastic leukemia (ALL)
Drug Type Mechanism Approval Indications References
Blinatumomab Bispecific T 
cell engager 
(BiTE)
A “bispecific” antibody with 
recognition domains for CD3 and 
CD19 to bring T cells into proximity to 
tumor cells to promote cytotoxicity
March 2018 Adult and pediatric patients with B- 
cell precursor ALL in first or second 
complete remission with MRD ≥0.1%
32 44 130
July 2017 Relapsed or refractory B- cell 




Philadelphia chromosome- negative 









Anti- CD22 antibody conjugated to a 
DNA- damaging calicheamicin payload 
that causes apoptotic death
August 2017 Adults with relapsed or refractory B- 
cell precursor ALL
21 54 101
Tisagenlecleucel CAR T cell 
therapy
Genetically modified autologous T 
cells expressing a chimeric receptor 
consisting of a CD19- recognition 
domain and 4- 1BB costimulatory 
domain to enhance expansion and 
persistence
August 2017 Patients up to 25 years of age with 
B- cell precursor ALL that is refractory 
or in second or later relapse
33 44
CAR, chimeric antigen receptor; FDA, Food and Drug Administration; MRD, minimal/measurable residual disease.
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with RR diffuse large B- cell lymphoma, based on findings 
from the pivotal JULIET study.40 Although immunothera-
pies in development are discussed in a separate section of 
this manuscript, it’s important to acknowledge that with 
84 active immunotherapy clinical trials for ALL registered 
with the US National Library of Medicine in June 2020, 
additional options will emerge every year.
Blinatumomab
Blinatumomab is a BiTE antibody construct that 
directs CD3 positive T cells to CD19- positive cells. 
CD19 is expressed on blast cells in >95% of cases of 
B- cell precursor ALL. Results from the landmark trials 
leading to blinatumomab’s approval are described in 
table 4.
Data from the phase III randomized clinical trial, 
TOWER, demonstrated that blinatumomab increased 
median OS compared with chemotherapy in patients 
with heavily pretreated Philadelphia chromosome 
negative (Ph−) B- ALL.20 The median OS was 7.7 
months in the blinatumomab group and 4.0 months 
in the chemotherapy group (p=0.01). Remission 
rates within 12 weeks after initiation of treatment 
were significantly higher in the blinatumomab group 
than in the chemotherapy group, both with respect 
to CR with full hematological recovery (34% vs 16%; 
p<0.001) and with respect to CR with full, partial, 
or incomplete hematological recovery (44% vs 25%; 
p<0.001). Treatment with blinatumomab resulted in 
a higher rate of event- free survival (EFS) than that 
with chemotherapy (6- month estimates, 31% vs 12%; 
HR for an event of relapse after achieving a CR with 
full, partial, or incomplete hematological recovery, or 
death, 0.55; 95% CI, 0.43 to 0.71; p<0.001), as well as a 
longer median remission duration (7.3 vs 4.6 months).
Based on data from these trials, the FDA granted full 
approval to blinatumomab in July 2017 for patients 
with RR B- ALL.31 Blinatumomab efficacy has also been 
evaluated as a therapy for patients with B- ALL who are 
in morphological remission after induction chemo-
therapy, but are positive for MRD. One hundred and 
sixteen patients received blinatumomab. Eighty- eight 
(78%) of 113 evaluable patients achieved a complete 
MRD response. In the subgroup of 110 patients with 
Ph– ALL in hematological remission, the relapse- 
free survival (RFS) at 18 months was 54%. Median 
OS was 36.5 months. In landmark analyses, complete 
MRD responders had longer median RFS (23.6 vs 
5.7 months; p=0.002) and OS (38.9 vs 12.5 months; 
p=0.002) compared with MRD non- responders.32 41 On 
March 29, 2018, the FDA approved blinatumomab for 
patients with B- ALL with positive MRD.31
Inotuzumab ozogamicin
Inotuzumab ozogamicin is a humanized anti- CD22 
monoclonal antibody conjugated to calicheamicin, a 
cytotoxic antibiotic agent. After the conjugate binds 
to CD22, the CD22- conjugate complex is rapidly inter-
nalized, and calicheamicin is released. Calicheamicin 
binds to the minor groove of DNA and induces double- 
strand breaks and subsequent apoptosis (table 3).42 
The FDA approved inotuzumab ozogamicin on 
August 17, 2017 for the treatment of patients with RR 
B- ALL.43 In the phase III INO- VATE trial, 109 patients 
with RR B- ALL, regardless of Philadelphia chromo-
some status, received inotuzumab ozogamicin. CR was 
achieved in 80.7% of patients who were treated with 
inotuzumab ozogamicin (95% CI, 72.1% to 87.7%) 
compared with 29.4% of patients (n=109) who were 
treated with standard- of- care (SOC) chemotherapy 













Adults with Ph− RR 
B- ALL
405 OS Median OS 7.7 months in 
blinatumomab group versus 
4.0 months in the chemotherapy 








Adults with Ph+ RR 
B- ALL
45 CR or CRh CR or CRh rate 36% (95% CI, 22% 




Phase I/II Children with RR B- ALL 93 total (49 
phase I) (44 
phase II)
MTD (phase 
I) CR (phase 
II)








Adults with B- 
ALL in first or later 
hematological CR and 





78% achieved MRD− 32
B- ALL, B- cell acute lymphoblastic leukemia; CR, complete response; CRh, CR with partial hematologic recovery; FDA, Food 
and Drug Administration; MRD, minimal/measurable residual disease; MTD, maximum- tolerated dosage; OS, overall survival; Ph, 
Philadelphia chromosome; RR, relapsed/refractory.
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(95% CI, 21.0% to 38.8%; p<0.001). Median OS for 
inotuzumab ozogamicin was 7.7 months (95% CI, 6.0% 
to 9.2%) versus 6.7 (95% CI, 4.9% to 8.3%) months 
for standard care; the 2- year OS rates were 23% (95% 
CI, 16% to 30%) versus 10% (95% CI, 5% to 16%), 
respectively. The primary objective to demonstrate 
significantly improved final OS with inotuzumab 
ozogamicin compared with standard care was not 
met. An exploratory post hoc restricted mean survival 
time analysis was applied to more precisely define the 
clinical benefit of inotuzumab ozogamicin. In this 
analysis, mean overall survival was longer in the inotu-
zumab ozogamicin group than in the standard- therapy 
group (mean [±SE], 13.9±1.10 months versus 9.9±0.85 
months; p=0.005).21
Tisagenlecleucel
Tisagenlecleucel is an anti- CD19 CAR T cell therapy, 
generated via the ex vivo genetic engineering and 
expansion of T lymphocytes obtained from the 
patient’s blood to incorporate a novel receptor into 
the T cell repertoire. Engineered T cells recognize 
and associate with antigen- positive malignant cells for 
elimination. In the phase I/IIa ELIANA trial, 75 chil-
dren and young adults (median age: 11 years, range: 3 
to 23 years) with RR B- ALL were treated with tisagenle-
cleucel. Of the enrolled patients, 46 (61%) had under-
gone prior allo- HCT. Before tisagenlecleucel infusion, 
72 of 75 patients (96%) received lymphodepleting 
chemotherapy. The overall remission rate was 81% 
(95% CI, 71% to 89%); 45 patients (60%) had CR, 
and 16 (21%) had CR with incomplete hematologic 
recovery (CRi). All patients who had a best overall 
response of CR with or without complete hematologic 
recovery were negative for minimal residual disease; 
95% (58 of 61) of these patients were negative by 
day 28. The median duration of follow- up among 
patients who received a tisagenlecleucel infusion was 
13.1 months. The rates of EFS and OS were 73% (95% 
CI, 60% to 82%) and 90% (95% CI, 81% to 95%), 
respectively, at 6 months and 50% (95% CI, 35% to 
64%) and 76% (95% CI, 63% to 86%) at 12 months.33
On August 30, 2017, tisagenlecleucel became the 
first ever FDA- approved CAR T therapy, gaining 
approval for the treatment of patients ≤25 years of age 
with B- ALL who have relapsed or have not responded 
after two previous lines of therapy.44 Approval was 
based on data from 63 patients, and among the infused 
patients, 52 (83%) achieved CR/CRi, all of which were 
MRD negative. Recently presented data suggest that 
responses to anti- CD19 CAR T therapy are excep-
tionally durable. Follow- up analyses from 97 patients 
enrolled in the ELIANA trial demonstrate 18- month 
RFS of 66% (95% CI, 52% to 77%) and 18- month OS 
probability of 70% (95% CI, 58% to 79%) with median 
OS not yet reached at the time of analysis.45
It is of note that the current FDA approval for tisagenle-
cleucel does not include adult patients with ALL aged 26 
years or older.46 As such, clinical trials investigating anti- 
CD19 CAR T cell therapy for the treatment of older adult 
patients with ALL are underway. Approval for this treat-
ment modality for adult patients with ALL is anticipated 
in the near future.
MRD status
Measurable residual disease (MRD) has been used to 
identify CR patients at a high risk of relapse. MRD is 
defined as the post- therapy persistence of leukemic 
cells at levels below morphological detection in the 
bone marrow or peripheral blood. MRD status of 
patients is considered a risk factor for relapse and is 
often used to select the next appropriate strategy for 
previously treated patients with acute leukemia. Blina-
tumomab is the only FDA approved immunotherapy 
in the ALL MRD positive disease setting at the time of 
guideline preparation.31
The role of MRD in treatment decisions for ALL 
remains an active area of investigation. Outcomes 
are generally poor for patients with detectable MRD 
at the time of allo- HCT.34 47 However, the prog-
nostic utility of MRD may vary depending on the 
assay used for measurement. MRD may be assessed 
by several methods including multicolor flow cytom-
etry (MFC), PCR, and next- generation sequencing 
(NGS). Although flow cytometry is typically consid-
ered the gold standard, molecular methods that iden-
tify leukemic cells with high sensitivity are also used 
in ALL.48 Studies are ongoing to determine whether 
detection of leukemic DNA above a certain threshold 
may consistently predict relapse after therapy. Newer 
sequencing methods may offer more robust predictive 
power. NGS- MRD predicted relapse and survival more 
accurately than MFC- MRD (p<0.0001), especially 
in the MRD- negative patients (relapse, 0% vs 16%; 
p=0.02; 2- year OS, 96% vs 77%; p=0.003). Post- HCT 
NGS- MRD detection was better at predicting relapse 
than MFC- MRD (p<0.0001), especially early after HCT 
(day 30 MFC- MRD positive relapse rate, 35%; NGS- 
MRD positive relapse rate, 67%; p=0.004).49 Ongoing 
studies are evaluating how best to incorporate NGS- 
based testing into patient care, especially in relation 
to allo- HCT.
Results of a large meta- analysis of 13,637 patients with ALL 
treated mainly with chemotherapy indicate that increased 
EFS significantly correlates with the presence of MRD- 
negative disease after treatment in both children and adults 
(pediatric: HR=0.23; 95% Bayesian CI (BCI): 0.18 to 0.28; 
adult: HR=0.28; 95% BCI, 0.24 to 0.33).36 Adults who were 
MRD- negative had EFS of approximately 64% at 10 years 
versus only 21% for those who were MRD- positive. The rela-
tive benefit in EFS of having achieved MRD negativity was 
comparable in both age groups.
Among patients receiving CAR T therapy, a subset who 
achieve MRD- negative status experience durable remis-
sions that persist with no further treatment.50 51 Although 
the factors that favor durable remission after achieving 
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MRD- negative status are under investigation, in one study 
with patients treated with CAR T cells, the EFS and OS 
were significantly better in the patients who achieved MRD- 
negative CR compared with those who did not (median EFS 
7.6 vs 0.8 months; p<0.0001; median OS 20.0 vs 5.0 months; 
p=0.014). Patients achieving MRD- negative CR showed that 
lower prelymphodepletion LDH concentration, higher 
prelymphodepletion platelet count, incorporation of fludar-
abine into the lymphodepletion regimen, and allo- HCT after 
CAR T cell therapy were associated with better EFS.50
Combination of allogeneic cell transplantation with 
immunotherapy
Guidelines concerning indications for allo- HCT have been 
generated by other societies and are outside the scope 
of this manuscript.26 52 However, it is important to address 
the role of allo- HCT and current immunotherapies, espe-
cially as more agents receive FDA approvals. Several publi-
cations have discussed the application of immunotherapy 
both before and after allo- HCT. Relapse after HCT is asso-
ciated with a very poor prognosis, yet immunotherapies 
may improve outcomes. Although further trials are needed, 
donor- derived CD19- targeted T cell infusions have been 
evaluated for relapsed B- ALL after haplo- HCT.53 Addition-
ally, trials assessing tisagenlecleucel (ELIANA) and blinatu-
momab (TOWER) included patients with B- ALL who had 
relapsed following prior allo- HCT. Both agents were effective 
and, importantly, tisagenlecleucel treatment did not result 
in new episodes of graft- versus- host disease (GVHD).20 33 
Inotuzumab ozogamicin and blinatumomab are both under 
investigation as salvage regimens after HCT. Importantly, 
inotuzumab ozogamicin carries a black- box warning for 
hepatotoxicity, including fatal and life- threatening sinusoidal 
obstruction syndrome (SOS)/veno- occlusive disease (VOD) 
in patients undergoing HCT after treatment.54
Allo- HCT after CAR T cell treatment has also been eval-
uated in clinical trials as a consolidation therapy to prevent 
relapse. In the ELIANA trial, eight patients while in reemis-
sion received allo- HCT after tisagenlecleucel.45
In a separate trial, among 44 patients who had a CR after 
the infusion of CAR T cells, 26 (59%) were observed who 
had no further therapy and 17 patients (39%) proceeded 
to transplantation. The median time from the CAR T cell 
infusion to transplantation was 74 days (range, 44 to 312). 
Of the 17 patients who underwent allo- HCT after the CAR 
T cell infusion, 5 patients were alive and had CRs, 6 had 
relapses, and 6 died from transplant- related toxic effects. 
Among the 32 patients who had a MRD- negative CRs, 
there was no significant difference in EFS and OS between 
patients who underwent transplantation and those who 
did not (p=0.64 for EFS and p=0.89 for OS by the log- rank 
test).55
Concerns have been raised about the use of checkpoint 
inhibitors prior to or after allo- HCT. While checkpoint inhi-
bition may augment the graft- versus- tumor effect, immune 
activation may place patients at risk of GVHD.56 57 The 
timing of administration may also play a role in determining 
the safety of checkpoint inhibition in a treatment plan that 
includes transplant. A review of 24 studies encompassing 
283 patients with a variety of hematological malignancies 
including 28 patients with AML and 4 patients with ALL 
found that the incidence of acute GVHD among patients 
receiving checkpoint inhibitor therapy prior to allo- HCT was 
56%, and 29% of patients developed chronic GVHD. There 
was a trend toward higher incidences of GVHD in patients 
with shorter median intervals between receiving the last dose 
of checkpoint inhibitor therapy and allo- HCT compared 
with patients having longer intervals.57 The duration during 
which GVHD risk may be increased by persistent immune 
activation induced by checkpoint inhibition in patients with 
leukemia is not currently known.
Panel recommendations
 ► While a number of immunotherapies do have a role in 
the treatment of patients with acute leukemia in various 
settings, clinical trial enrollment should be considered at 
each juncture.
 ► New, experimental drugs should be administered at 
centers that have proper support, infrastructure, and 
subspecialties.
 ► Patients with relapsed B- ALL should receive immu-
notherapy as a bridging therapy to induce remission 
prior to allo- HCT.
 ► Options for patients with relapsed ALL after one line 
of prior therapy include clinical trial enrollment, treat-
ment with blinatumomab or inotuzumab ozogamicin, or 
allo- HCT.
 ► For patients with relapsed B- ALL and a high disease 
burden, inotuzumab ozogamicin should be considered 
first followed by blinatumomab for persistent disease 
or MRD positivity, based on the clinical experience and 
consensus of the Expert Panel.
 ► Because inotuzumab ozogamicin increases the risk of 
SOS/VOD in subsequent transplants, the number of 
cycles should be limited if allo- HCT is planned.
 ► Patients with newly diagnosed B- ALL who are MRD 
positive after undergoing induction chemotherapy 
should be offered blinatumomab.
 ► CAR T cell therapy is strongly recommended for 
patients with relapsed ALL after second- line and/or 
third- line therapy.
 ► Outcomes for MRD‐positive patients are generally poor; 
therefore, enrollment into a clinical trial should be 
considered to help achieve an MRD‐negative status.
IMMUNOTHERAPY FOR THE TREATMENT OF PATIENTS WITH 
AML
To date, relatively few immunotherapy approaches have 
been approved for the treatment of patients with AML 
compared with those available for the treatment of 
patients with ALL, although many are in clinical trials and 
some show promising preliminary results. One possible 
cause for this discrepancy is the difficulty in identifying 
targetable antigens on myeloid cells that allow for safe 
anticancer activity with defined long- term effects on the 
patient. Currently, the only approved immunotherapeutic 
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strategies for treating AML are allo- HCT and the CD33- 
targeting ADC GO. However, several research programs 
and clinical trials are currently underway hoping to 
further the repertoire of therapies such as checkpoint 
inhibitors, unconjugated antibodies, BiTEs, and CAR T 
cell therapies in the treatment of AML.
Approved agents and indications
Gemtuzumab ozogamicin
GO, an anti- CD33 ADC, using a calicheamicin- derivative 
cytotoxic drug, was the first ADC approved for human use 
by the FDA for AML. On binding to CD33, GO is rapidly 
internalized, leading to the intracellular release of cali-
cheamicin, a potent DNA- damaging agent that causes 
single- strand and double- strand breaks, which leads to 
checkpoint activation, cell cycle arrest, and the activa-
tion of cell death pathways.58 GO was granted acceler-
ated approval in the USA in 2000 for patients aged 60 
years or older with CD33- positive AML in first relapse and 
who are not considered to be candidates for cytotoxic 
chemotherapy. Accelerated approval was granted after 
promising results from a single phase I study and three 
phase II trials, where the overall response rate (ORR) was 
30% in a total of 142 patients.59 After the initial approval, 
however, GO was increasingly recognized to be associated 
with hepatotoxicity and severe SOS,60 leading the FDA 
to issue a black- box warning. The drug was voluntarily 
withdrawn in 2010 after a postapproval phase III clinical 
trial that found an increase in treatment- related mortality 
with no improvement in CR rate, disease- free survival, or 
overall survival (OS), with the addition of GO to standard 
induction or postconsolidation therapies.61
However, recently, GO has reemerged as an option for 
the treatment of AML. In 2017, GO was reapproved for 
the treatment of newly diagnosed CD33- positive AML 
in adults (both alone or in combination with induction 
chemotherapy) and as a single agent for the treatment of 
RR CD33- positive AML in adults and in pediatric patients 
aged 2 years and older.30 The studies leading to reap-
proval are summarized in table 5. Additionally, a 2014 
meta- analysis of five trials encompassing 3325 patients 
found that the addition of GO to induction chemo-
therapy significantly reduced the risk of relapse (OR 
0.81; p=0.0001) and improved OS at 5 years (OR 0.90; 
p=0.01).62
The current FDA approval indicates GO as both a single 
agent and in combination with chemotherapy during 
induction and consolidation for newly diagnosed AML in 
adults and in pediatric patients aged 1 month and older. 
In the RR setting, GO is approved for adult patients and 
is used as a monotherapy.30
MRD status
The importance of the MRD status of patients has also 
been investigated in AML settings. Several strategies 
exist to assess MRD status, including MFC, qRT PCR, and 
NGS.25 In one study of 482 patients aged 18 to 65 years 
with newly diagnosed AML, molecular MRD status deter-
mined via NGS correlated with risk of relapse in patients 
who achieved CR after induction therapy.35 The detec-
tion of molecular MRD was associated with a significantly 
higher relapse rate than no detection (55.4% vs. 31.9%; 
HR, 2.14; p<0.001), as well as with lower rates of RFS 
(36.6% vs. 58.1%; HR for relapse or death, 1.92; p<0.001) 
and OS (41.9% vs. 66.1%; HR for death, 2.06; p<0.001). 
In a meta- analysis, pretransplant MRD was associated with 
worse leukemia- free survival (HR=2.76; 95% CI, 1.90 to 
4.00), (OS HR=2.36; 95% CI, 1.73 to 3.22), and cumula-
tive incidence of relapse (HR=3.65; 95% CI, 2.53 to 5.27), 
but not non- relapse mortality (HR=1.12; 95% CI (0.81 
Table 5 Clinical trials using GO in AML
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AML, acute myeloid leukemia; CR, complete response; CRR, complete response rate; EFS, event- free survival; GO, Gemtuzumab 
ozogamicin; OS, overall survival; RR, relapsed/refractory.
9Boyiadzis MM, et al. J Immunother Cancer 2020;8:e000810. doi:10.1136/jitc-2020-000810
Open access
to 1.55). These associations held regardless of detection 
method, conditioning intensity, and patient age.63
Combination of allogeneic cell transplantation with immunotherapy
Immunotherapies for the treatment of AML remain an 
ongoing subject of research, and data on the optimal inte-
gration of these novel agents into established approaches 
are limited. Given that graft- versus- leukemia effects are 
an important contributor to outcomes after allo- HCT,10–12 
caution is warranted when incorporating any immune- 
targeting modality into a treatment plan that includes 
transplant. One phase I/Ib clinical trial assessing the anti- 
cytotoxic T- lymphocyte- associated protein 4 (CTLA-4) 
checkpoint inhibitor ipilimumab after allo- HCT in 
patients with relapsed hematological malignancies—
including 12 patients with AML—observed 1 year OS 
of 49% with 14% of total patients (4/28) developing 
GVHD.56 Another phase I study demonstrated that pedi-
atric patients with AML who received reduced- intensity 
conditioning allo- HCT followed by consolidation therapy 
involving GO had a probability of developing grades II to 
IV acute and chronic GVHD of 21% and 33.5%, respec-
tively. Probability of OS after allo- HCT and GO consol-
idation at 1 and 5 years was 78% and 61%, respectively. 
Probability of 5- year EFS after allo- HCT and GO consoli-
dation in patients in CR1 was 78%.64
Although FDA- approved immunotherapies have 
demonstrated enhanced curative potential compared 
with standard treatment modalities, several patients will 
not respond or will relapse after immunotherapy- induced 
remissions. The pathophysiology of AML postrelapse 
remains an ongoing and important area of study. Dereg-
ulation of pathways involved in T cell- mediated allorecog-
nition has been identified as a feature and driver of AML 
relapses after allo- HCT,65 including downregulation of 
major histocompatibility complex class II genes involved 
in antigen presentation, loss of HLA class I antigens in 
the case of HLA- matched and HLA- mismatched trans-
plants, and the acquisition of de novo mutations.66–68 
These changes potentially offer insights that could even-
tually be translated into personalized therapies.
Relapse after allo- HCT in AML is generally associated 
with a very poor prognosis without active treatment. 
Remission may be achieved through the administration of 
donor lymphocyte infusion (DLI). A retrospective, anal-
ysis of 399 patients with AML in first hematological relapse 
after allo- HCT estimated that DLI prolonged survival rates 
at 2 years to 21%±3% compared with 9%±2% for patients 
not receiving DLI.69 The use of DNA methyltransferase 
inhibitors (DNMTs; azacitidine, Aza; or decitabine, DAC) 
have been used in conjunction with DLI to induce antileu-
kemia CD8+ T cell responses by enhancing the expression 
of epigenetically silenced tumor antigens. The prospec-
tive multicenter AZARELA trial reported encouraging 
ORRs for Aza+DLI treatment after relapse, including five 
patients continuing CR for a median of 777 days without 
any additional treatment. The incidence of acute and 
chronic GVHD was 37% and 17%, respectively, and all 
cases were mild.70 Several other studies have demon-
strated similar benefits with DNMTs, with or without DLI, 
for relapsed patients after allo- HCT.69 71–73 It is currently 
not known whether DLI combined with DNMTs is more 
effective than either therapy alone. Ongoing studies are 
evaluating strategies to enhance response rates for DLI 
post- transplant, including in combination with immuno-
modulatory agents.
Panel recommendations
 ► While many immunotherapy approaches may have a 
role in the treatment of patients with AML in various 
settings, clinical trial enrollment should be consid-
ered at each juncture.
 ► GO may be added in favorable and possibly 
intermediate- risk patients with AML during induction 
chemotherapy.
 ► GO should be considered at the time of AML relapse 
and in newly diagnosed patients with AML who are not 
eligible to receive intensive induction chemotherapy.
 ► Outcomes are generally worse after allo- HCT for 
patients who achieve morphological remission after 
induction chemotherapy, yet display persistent MRD. 
Further studies are needed to identify therapeutic 
options for these patients. Therefore, enrollment into 
a clinical trial should be considered to help achieve an 
MRD‐negative status.
EMERGING IMMUNOTHERAPIES FOR THE TREATMENT OF 
PATIENTS WITH ACUTE LEUKEMIA
A number of novel agents and strategies are being tested 
in preclinical and clinical settings. Promising results have 
been reported for both antibody- based and cell- based ther-
apies, especially in the rapidly burgeoning CAR T cell field. 
As novel immunotherapies demonstrate safety and efficacy 
in clinical trials, more options will emerge for practicing 
clinicians. Because many of these agents have not yet been 
approved by the FDA, the committee emphasizes that new 
experimental drugs should only be administered at centers 
with proper support, infrastructure, and subspecialties in 
place to monitor outcomes and adverse events (AEs).
Agents and indications
Rituximab
Rituximab, a chimeric anti- CD20 antibody, has been eval-
uated with combination chemotherapy for patients with 
B- ALL demonstrating improved EFS as well as OS benefit 
and molecular CR rates (table 6).15 74 Although rituximab 
is not FDA approved for the treatment of CD20+ ALL, 
rituximab is being used in combination with ALL chemo-
therapeutic regimens during induction, consolidation, 
and maintenance therapies.
Bispecific cell engager therapies
Based on the success of blinatumomab in ALL, efforts 
are underway to develop similar agents targeting anti-
gens specific for AML, such as CD123 and CD33.75 Addi-
tional studies for bispecific cell engagers targeting the 
leukemic cell antigen CD33 are ongoing. A phase I study 
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of the CD33/CD3 BiTE AMG330 demonstrated accept-
able safety profiles in 35 patients with RR AML.76 Studies 
are also ongoing for another CD33/CD3 bispecific cell 
engager, AMV564, which demonstrated safety and anti-
leukemia activity in a first- in- human trial in patients with 
RR AML.77
A study evaluating a trispecific killer engager (TriKE) 
therapy engaging CD16 on natural killer (NK) cells and 
targeting CD33 on AML/MDS with an interleukin (IL)-15 
linker between the two domains has just been opened for 
accrual in AML (NCT03214666). The drug differs from 
bispecific cell engagers due to the NK cell activation it 
provides while bringing them in proximity to malignant 
blasts due to the presence of the IL-15 linker domain. At 
the time of publication, the single- center phase I/II clin-
ical trial is enrolling patients with refractory AML defined 
as failure to achieve remission after at least three induc-
tion attempts or relapsed AML who are not a candidate 
for HCT after at least one re- induction attempt, as well as 
patients with prior HCT relapse beyond 3 months without 
active GVHD.
Antibody–drug conjugates
Based on extremely promising preclinical data, several 
ADCs targeting different surface markers and carrying 
different payloads have begun making their way through 
clinical trials. Initial results from the ongoing SIERRA 
study (NCT02665065) have indicated safety and feasibility 
for Iomab- B, an anti- CD45 ADC- carrying radioactive 131I, 
as a bridging therapy before transplant for patients with 
RR AML. Analysis of the first 25% of enrolled patients 
(n=38) showed a rapid reduction in the leukemia burden 
after Iomab- B treatment, setting the stage for successful 
engraftment after allo- HCT.78 Another ADC, IMGN632, 
a CD123- targeting antibody linked to a novel DNA- 
alkylating agent, has demonstrated in an ongoing phase 
I study objective responses in RR AML, including 1 CR 
and 3 CRi, with no dose- limiting toxicities.79 Additionally, 
the CD30- specific ADC brentuximab vedotin has demon-
strated favorable safety in a phase I trial (NCT01830777) 
when administered in combination with a conventional 
mitoxantrone, etoposide, and cytarabine reinduc-
tion chemotherapy regimen for patients with CD30+ 
RR AML.80
Checkpoint inhibitors
To date, immune checkpoint inhibitors, which have 
demonstrated efficacy for treating patients with solid 
tumors and classical Hodgkin lymphoma, have not had 
similar significant success in acute leukemias. Ongoing 
studies are evaluating the combination of checkpoint 
inhibition with blinatumomab for B- ALL, and one phase 
I study reported an MRD- negative CR rate of 80% in 
five heavily pretreated patients with a significant base-
line disease burden.81 Checkpoint inhibitors remain 
under investigation as single agents for maintenance 
following allo- HCT, especially in the context of AML, 
where some studies indicate that checkpoint inhibition 
augments the graft- versus- leukemia effect as well as in 
combination regimens with chemotherapy. Combina-
tions of nivolumab (an anti- PD-1 antibody), in combina-
tion with hypomethylating agents (HMAs) or induction 
chemotherapy have recently been reported.82–84 In one 
example, patients with RR AML received nivolumab with 
azacitidine. The overall response rate (ORR) was 33% 
including 15 (22%) CR/CRi, 1 partial response (PR), and 
7 patients with hematological improvement maintained 
for 6 months or longer. The ORR was 58% and 22%, in 
HMA- naive (n=25) and HMA pretreated (n=45) patients, 
respectively.82 In another example, patients with RR AML 
received pembrolizumab following high- dose cytarabine. 
The ORR of 10 evaluable patients was 50%, with 4 CR/
CRi.85 Other promising results emerged from a phase II 
trial evaluating a triplet regimen combining nivolumab 
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chromosome.
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with ipilimumab and azacitidine, with a CR/CRi rate of 
36% and a 1- year survival rate of 45% in a cohort of 31 
patients with RR AML.86 These, and several other studies, 
are currently ongoing.
CAR T cell therapies
Bolstered by the success of CD19 targeting CAR T 
cell therapies in the pediatric B- ALL setting, ongoing 
research is evaluating novel agents for patients with ALL, 
new approaches that can provide adult patients with 
ALL access to CAR T cell treatment, and strategies for 
the treatment of patients with AML. Several studies are 
working to develop CAR T cell therapies targeting non- 
CD19 antigens for patients with CD19- negative disease or 
for those who relapse after anti- CD19 CAR T cell infu-
sion. Among the most mature are CD22- directed CAR T 
cells for the treatment of RR B- ALL. Fry and colleagues 
reported initial results from a phase I trial testing a new 
CD22- targeted CAR in 21 children and adults, including 
17 who were previously treated with CD19- directed immu-
notherapy. Dose- dependent antileukemic activity was 
observed, with CR obtained in 73% (11/15) of patients 
receiving ≥1×106 CD22- CAR T cells per kilogram body 
weight, including in five out of five patients with CD19dim 
or CD19- negative B- ALL. Median remission duration was 
6 months. Relapses were associated with diminished CD22 
site density that likely permitted CD22+ cell escape from 
killing by CD22- CAR T cells.28 A follow- up report on that 
trial included 52 patients. 36 patients (69.2%) had under-
gone HCT; 30 (57.7%) had prior CD19 CAR; 22 (42.3%) 
had prior blinatumomab; and 28 (53.8%) subjects had 
a CD19- negative population, including 2 who were 
inherently partial CD19 -negative without prior targeted 
therapy. The CR rate was 72.5% overall; 84% at the 
current dose level. This included CRs seen in subjects who 
were non- responders to CD19 CAR T cell therapy and/or 
blinatumomab. The longest remission was >3 years (n=1) 
post- CAR T cell infusion. Relapse occurred at a median 
of 6 months postinfusion in 23 (64%) subjects primarily 
due to CD22 modulation. Twelve patients proceeded to 
HCT following CD22 CAR T cell therapy.87 Another study 
in 34 pediatric and adult patients with RR B- ALL who did 
not respond from previous CD19 CAR T cell therapy were 
treated with CD22 CAR T cell therapy found that CR or 
CRi was achieved in 24 of 30 patients (80%) that could be 
evaluated on day 30 after infusion, which accounted for 
70.5% of all 34 enrolled patients.88
CAR T cell therapies for the treatment of patients 
with AML are also in development. One promising 
strategy currently being assessed in multiple clinical 
trials involves CAR T cell therapies that target CD33 on 
myeloid cells. Anti- CD123 CAR T cell therapies for the 
treatment of patients with RR AML are also being evalu-
ated.89 Other clinical trials are ongoing, including CAR 
T cells targeted against CD7 (NCT04033302) and FLT3 
(NCT03904069).
Other cell therapies
Beyond CAR T cells, several other immune effector 
cell- based therapies are undergoing evaluation. One 
approach involves the infusion of donor lymphocytes 
genetically engineered to express the herpes simplex 
virus thymidine kinase (the so- called “suicide gene”) 
after haploidentical HCT.90 Other studies are evaluating 
additional strategies, including infusion of T regulatory 
type 1 cells after HCT as well as personalized NK cell 
therapy after chemotherapy, and umbilical cord blood 
transplant.
Advances have been made in cytokine- induced NK cell 
therapy as well as in the infusion of autologous T cells 
specific for WT1 for AML. A first- in- human phase I clinical 
trial demonstrated that adoptively transferred allogeneic 
NK cells induced to a memory- like phenotype through 
preincubation with IL-12, IL-15, and IL-18 proliferated 
and expanded in patients with AML and demonstrated 
robust responses against leukemia targets.91 Donor- 
derived WT1- specific CD8+ cytotoxic T cells have demon-
strated direct evidence of antileukemic activity92 and 
prophylactic infusion of Epstein- Barr virus- specific donor 
CD8+ T cells transduced with a T cell receptor specific 
for WT1 post- HCT was associated with 100% RFS in 12 
patients with a median follow- up of 44 months, while a 
concurrent comparative group of 88 patients with similar 
risk AML had 54% RFS (p=0.002).93
As personalized cell therapy requires several weeks of 
production, there is a growing interest in off- the- shelf 
NK cell products. One way to accomplish this goal is by 
differentiation of induced pluripotent stem cells (iPSC) 
into an unlimited supply of cryopreserved NK cells for 
immediate availability and allowing for multidose strate-
gies.94 One example of this strategy, FT516, which consists 
of iPSC- derived NK cells engineered with a high- affinity, 
non- cleavable CD16 Fc receptor, has entered phase I/Ib 
clinical trials in patients with primary refractory AML and 
relapsed AML (NCT04023071).
Panel recommendations
 ► Patients should be treated with FDA- approved thera-
pies, if available, with clinical trial enrollment consid-
ered at each juncture.
 ► New, experimental drugs should be administered 
at prepared institutions. Institutions need to have 
proper support, infrastructure, and subspecialties.
 ► The use of rituximab in patients with CD20+ B- ALL is 
recommended.
ROLE OF IMMUNOTHERAPY POST-CAR T CELL THERAPY
CAR T cell therapies have offered significant survival bene-
fits for patients with ALL and data suggest that responses 
are durable. In some cases, however, CAR T cell therapy is 
ineffective due to either lack of the targetable antigen or 
antigen loss after initial therapy. Therefore, many novel 
CAR T cell therapies are under investigation to provide 
secondary options for these patients. In some cases, other 
immunotherapeutics may be options for patients who 
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have relapsed or are refractory to FDA- approved CAR T 
cell therapies.
Although trials are underway for tisangenlecleucel as 
treatment for pediatric and young adult patients with 
B- ALL who received first- line treatment and are MRD 
positive at the end of consolidation therapy (CASSI-
OPEIA, NCT03876769), the current FDA approval is 
for refractory patients or in patients in second relapse 
or later. Relapse after CAR T cell therapy is sometimes 
due to the loss of the target antigen.28 45 The prognosis 
of patients who relapse post- CAR T cell administration 
is often considered poor, especially considering that the 
anti- CD19 blinatumomab is also rendered ineffective in 
patients with CD19 loss.
The availability of multiple CD19- targeting therapies 
including BiTEs and CAR T cells makes decisions on 
optimal treatment sequencing challenging, especially 
given the possibility for relapse mediated by antigen loss.95
Options for patients who relapse post- CAR T cell therapy 
include salvage chemotherapy, clinical trial enrollment, 
allo- HCT, or retreatment with CAR T cells (potentially 
targeting different antigens, depending on the mecha-
nism of relapse). Allo- HCT transplant is potentially an 
option for patients who relapse after CAR T cell therapy, 
but these patients are often ineligible for transplant.
There are multiple studies investigating CAR T cell 
therapies that target antigens other than CD19 for the 
treatment of patients with CD19- negative ALL. There 
have been encouraging reports of therapeutic response 
in patients who have relapsed after CD19- targeted CAR 
T- cell therapy. For example, one study notes that patients 
with CD19- negative B- ALL displayed a median remission 
duration of 6 months after receiving anti- CD22 CAR T 
cell therapy. Of note, relapse due to loss of CD22 was also 
observed in this trial.28 As such, there are clinical studies 
investigating bispecific CAR T cell therapies that target two 
antigens concurrently to increase efficacy and reduce the 
risk of relapse.96 In one phase 1 trial of bispecific CD19/
CD22 CAR T cells, CR was achieved in 5/7 (71%) RR 
ALL patients by day 21, 4 of which were minimal residual 
disease negative. Therapy was well tolerated with no dose 
limiting toxicities. CRS occurred in 5 subjects (Grade 1) 
with 2 of these subjects experiencing mild neurotoxicity. 
(Grade 1).97 Another study of the CD19/CD22 ‘cocktail 
CAR T cell’ approach for RR B- ALL demonstrated a 100% 
CR/CRi rate on day 20 to 30 after infusion in 15 patients 
with 14/15 (93.3%) achieving MRD negativity.98 A very 
low treatment- related toxicity was observed in this trial. 
Only 1 patient experienced grade 3 CRS and another 
patient (6.7%) developed grade 3 central nervous system 
toxicity; all other patients were CRS grade<2 and CNS 
grade 0.
Panel recommendations
 ► With very few options available to patients who relapse 
after CAR T cell therapy, clinical trial enrollment 
should be strongly considered.
 ► For patients with ALL who relapse or are refractory to 
CAR T cell therapy, a consensus could not be reached 
to recommend one preferred treatment. Potential 
options could include CAR T cell therapy targeting 
different antigens, blinatumomab, or allo- HCT (if 
eligible).
RECOGNITION AND MANAGEMENT OF IMMUNE-RELATED AES 
IN PATIENTS WITH ACUTE LEUKEMIA BEING TREATED WITH 
IMMUNOTHERAPY
Immune- related AEs are of significant concern in the field 
of immuno- oncology. Immunotherapies have distinct and 
significant toxicities requiring skilled management. SITC 
has published a textbook guide to managing immuno-
therapy toxicity as well as a consensus statement from 
the Toxicity Management Working Group concerning 
the management of toxicities after treatment with check-
point inhibitors.99 Toxicity management after CAR T cell 
therapy for hematological malignancies is described in 
a 2018 review publication from SITC.17 At the time of 
publication, two additional SITC clinical practice guide-
lines for the recognition and management of immune- 
related AEs for immune effector cell and checkpoint 
inhibitor therapies are in preparation. Additionally, the 
American Society for Transplant and Cellular Therapy 
has published consensus guidelines for grading CRS and 
neurological toxicity after CAR T cell therapy.100
AEs arising during treatment for ALL with immuno-
therapy are distinctive and must be recognized early and 
managed appropriately. Concerning inotuzumab ozoga-
micin, 46% of patients treated with inotuzumab ozoga-
micin in the INO- VATE trial experienced ≥grade 3 AEs, 
similar to the rate and profile of ≥grade 3 AEs in patients 
who received SOC chemotherapy (43%). VOD occurred 
more frequently in the inotuzumab ozogamicin group 
than in the standard- therapy group (in 11% (15 patients) 
vs 1% (1 patient)). Of the 48 patients in the inotuzumab 
ozogamicin group who underwent stem cell transplanta-
tion after the trial, 10 had VOD after transplantation. The 
median time to the development of VOD associated with 
transplantation in the inotuzumab ozogamicin group was 
16 days (range, 3 to 39 days).21 Recent consensus recom-
mendations for the prevention and monitoring of VOD 
associated with inotuzumab ozogamicin include: avoid 
HCT conditioning regimens containing dual alkylating 
agents, use prophylactic medicines in patients proceeding 
to HCT, limit treatment with inotuzumab ozogamicin to 
2 cycles, monitor patient weight for fluid retention, and 
frequently assess liver function.101
Both blinatumomab and CAR T cell therapies can result 
in serious AEs including CRS and neurotoxicities.102 103 
These two events can be fatal if not properly managed. 
CRS was the most common AE reported across all CAR 
T cell clinical trials, with an incidence as high as 74% to 
100% for CD19- directed CAR T cells.33 103–105 CRS can 
present with a variety of symptoms. Mild symptoms of CRS 
include fever, headache, rash, arthralgia, and myalgia. 
More severe cases are characterized by hypotension that 
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can progress to an uncontrolled systemic inflammatory 
response with vasopressor- requiring circulatory shock, 
vascular leakage, disseminated intravascular coagulation, 
and multiorgan system failure.100 103 106–112
Several descriptions of management strategies for CAR 
T cell- associated CRS have been published, which gener-
ally encompass supportive care and anti- IL-6 therapies to 
break the cycle of inflammation.103 109 110 113–115 110 CRS 
toxicity may be mitigated by modifying the dosing of CAR 
T cells to attenuate peak expansion and proliferation, as 
was demonstrated in a recent report using fractionated 
dosing scheme of infused CAR T cells that demonstrated 
high response rates with acceptable tolerability in adult 
patients with ALL.116
Neurotoxicity has been reported in nearly every study 
involving CD19- directed T cells, including CAR T cells 
and blinatumomab. In the TOWER trial evaluating 
blinatumomab for the treatment of patients with ALL, 
25/267 (9.4%) patients experienced neurotoxicities.20 
Neurotoxicities were also observed in the ELIANA trial of 
tisagenlecleucel, where 40% of patients (30/75) experi-
enced an event of any grade, and 13% of patients (10/75) 
experienced a grade 3 event.33 Risk factors for neurotox-
icity after CAR T cell treatment include extramedullary 
disease younger age, pre- existing neurological comorbid-
ities, higher total CAR T cell doses, early and/or severe 
CRS, and cytopenias.114 117 Unlike CRS, neurotoxicity 
secondary to CAR T cell treatment does not respond to 
tocilizumab.33 117–120
Panel recommendations
 ► For patients participating in clinical trials using CAR 
T cells, toxicity should be assessed and managed as 
per study protocols.
 ► Patients treated with CAR T cells or blinatumomab 
should be monitored vigilantly for signs of CRS and 
neurotoxicity including (but not limited to) fever, 
hypotension, and altered mental state.
 ► The management of CRS or neurotoxicity secondary 
to approved CAR T cell therapy or blinatumomab 
should follow established guidelines.
PATIENT SUPPORT AND QUALITY OF LIFE (QOL) 
CONSIDERATIONS
While immunotherapy may provide a significant and 
durable antitumor response for many patients, the appro-
priateness of any treatment option ultimately depends on 
patient- specific considerations. Although the likelihood 
for deep and durable response is the utmost priority in 
treatment selection, it is important to consider the poten-
tial effects on patient satisfaction and QoL for a planned 
intervention. Several analyses of QoL during chemo-
therapy in patients with acute leukemia have found that 
intensive induction regimens are linked to detrimental 
physical and psychological effects, such as fatigue, loss of 
physical function, and depression.121 122 However, several 
studies have also found that, in general, QoL improves 
significantly when patients are in remission.121 122
Immunotherapies offer the potential for prolonged 
remissions in some subsets of patients. Yet, although 
the side effects of immunotherapy might be more toler-
able for patients than those that accompany cytotoxic 
drugs, the toxicities associated with immunotherapeutic 
approaches may be life- threatening in some cases; for 
example, CRS due to CAR T cell and BiTE therapies and 
VOD/SOS after some ADCs. Thorough patient educa-
tion, as well as ongoing dialog among all members of a 
patient’s care team, is critical to ensure that the individu-
alized and unique aspects of immunotherapy are under-
stood, as well as the importance of promptly reporting 
any toxicity.
Due to the rapidly evolving nature of the field, rela-
tively few large- scale QoL assessments directly comparing 
immunotherapeutic approaches with SOC treatment 
for patients with acute leukemia have been completed. 
From the available literature, however, recently approved 
immunotherapies compare favorably with intensive 
chemotherapy and allo- HCT in terms of patient- reported 
outcomes and QoL.
An analysis of patient outcomes in the phase III TOWER 
study of blinatumomab in adults with RR Ph− B- cell 
precursor ALL found patients who were treated with SOC 
chemotherapy (n=95) reported significant deteriorations 
in several functional measures (physical, role, and social) 
and symptoms as measured by the 30- item European Orga-
nization for Research and Treatment of Cancer Quality of 
Life Questionnaire (QLQ- C30) and markedly decreased 
overall global health status/QoL scores relative to blina-
tumomab. Furthermore, the time to clinically meaningful 
deterioration in HRQL or death was delayed for blinatu-
momab versus chemotherapy across all EORTC QLQ- C30 
scales.123 n the phase III INO- VATE trial, patients with RR 
B- ALL who received inotuzumab ozogamicin 124reported 
better QOL, functioning, and symptom scores (except 
for constipation and emotional functioning).124 Similarly, 
an analysis of 58 patients with RR B- ALL aged 8–23 years 
treated with tisagenlecleucel in the phase II ELIANA trial 
demonstrated improvements in patient- reported QoL 
scores for all measures at month 3 after infusion with a 
mean change from baseline of 13.3 (95% CI, 8.9 to 17.6) 
for the pediatric quality of life inventory (PedsQL) total 
score and 16.8 (95% CI, 9.4 to 24.3) for the EQ- 5D Visual 
Analogue Scale.20
Depending on the immunotherapeutic agent used, 
hospitalization and monitoring during dosing and in 
the subsequent weeks may be required, which can affect 
a patient’s QoL and ability to work. For example, blina-
tumomab requires continuous intravenous infusion over 
4 weeks and hospitalization is recommended for the first 
9 days of the first cycle for RR disease and 3 days of hospi-
talization for cycle 1 in the MRD setting. Additionally, 
patients are advised to refrain from driving and engaging 
in hazardous occupations or operating heavy or poten-
tially dangerous machinery while receiving blinatum-
omab.31 Tisagenlecleucel requires patients to stay within 
proximity of their treatment center for the first month 
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after infusion and, patients must be monitored two to 
three times during the first 7 days after treatment.46
Financial distress related to cancer also takes a substan-
tial toll on patient QoL.125 Immunotherapies for leukemia 
are expensive. Importantly, patients may incur additional 
expenses, such as transportation to and from the hospital 
or accommodations nearby during treatment, further 
highlighting that unequal access to these emerging 
therapies.
Despite high prices, immunotherapeutic agents fare 
favorably in cost- effectiveness analyses, offering significant 
gains in life years and QoL years (quality- adjusted life years 
(QALYs)) for patients. A recent cost- effectiveness study of 
CAR T cell therapy versus SOC for pediatric patients with 
B- ALL found that tisagenlecleucel had a total discounted 
cost of US$667,000 (including hospital stays and other 
expenses), with 10.34 discounted life years gained and 
9.28 QALYs gained, which amounted to an incremental 
cost- effectiveness ratio of approximately US$42,000 per 
life year gained and approximatelyUS$46,000 per QALY 
gained compared with clofarabine.126 In adults with RR 
Ph− B- ALL, blinatumomab was found to yield 1.92 addi-
tional life years and 1.64 additional quality- adjusted life 
years (QALYs) compared with SOC at an incremental cost 
of US$180,642. The incremental cost- effectiveness ratio 
for blinatumomab vs SOC was estimated to be $110,108/
QALY gained in the base case.127 In the UK, the National 
Institute for Health and Care Excellence estimated 
substantial improvement in survival with inotuzumab 
ozogamicin compared with SOC, providing an additional 
5.2 life years and 2.2 QALYs.128The deterministic incre-
mental cost- effectiveness ratio was between £33,749 and 
£37,497 per quality- adjusted life- year gained compared 
with standard of care.
Panel recommendations
 ► Prior to being treated with immunotherapy, patients 
and caregivers should be educated about potential 
AEs and given clear instructions for call parameters 
for any toxicities.
 ► Study protocols for new, investigational agents should 
incorporate QoL assessment using validated tools.
CONCLUSION
Once almost universally fatal, the 5- year survival rate for 
acute leukemia has risen to 63% in the US.129 The advent 
of immunotherapy has expanded the available options 
in the treatment repertoire for acute leukemia, although 
progress has been slower in the AML setting. Every year, 
novel agents including BiTEs, CAR T cell therapies, and 
ADCs continue to demonstrate impressive response rates 
with favorable toxicity profiles across a variety of disease 
states. Despite these advances, many patients remain inel-
igible for immunotherapeutic treatments, and relapses 
after some of the newer modalities remain associated 
with a very poor prognosis. In the future, the indications 
for existing therapies are likely to continue to expand 
and novel agents with potentially distinct mechanisms 
of actions will be approved. Promising areas for future 
research in leukemia include improvements in CAR 
constructs and combining CAR T cell therapies with 
other immunotherapy approaches as well as the develop-
ment of additional bispecific monoclonal antibodies. In 
AML specifically, there is great potential in efforts aimed 
at targeting novel proteins that might be more effective 
or more specific to early leukemia progenitors for novel 
antibodies such as CLL1, WT1, and PR1 as well as the 
development of CAR T cells for myeloid leukemias with 
‘off switches’ to minimize long- term myelosuppression. 
Therefore, as the field continues to develop, these recom-
mendations will be updated.
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